[1] Rinella M E,Lazarus J V,Ratziu V,et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology,2023,78(6):1966-1986. [2] Targher G,Valenti L,Byrne C D. Metabolic dysfunction-associated steatotic liver disease[J]. N Engl J Med,2025,393(7):683-698. [3] Romeo S,Sanyal A,Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease[J]. Cell Metab,2020,31(1):35-45. [4] Romeo S,Kozlitina J,Xing C,et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet,2008,40(12):1461-1465. [5] Speliotes E K,Yerges-Armstrong L M,Wu J,et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits[J]. PLoS Genet,2011,7(3):e1001324. [6] Chen Y,Du X,Kuppa A,et al. Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease[J]. Nat Genet,2023,55(10):1640-1650. [7] 吴芃萱,刘晖,郑素军.伴有脂肪肝的遗传代谢性肝病诊断策略[J].实用肝脏病杂志,2026,29(4):481-484. [8] BasuRay S,Wang Y,Smagris E,et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis[J]. Proc Natl Acad Sci U S A,2019,116(19):9521-9526. [9] Grimaudo S,Pipitone R M,Pennisi G,et al. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2020,18(4):935-944.e933. [10] Xia M F,Lin H D,Chen L Y,et al. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes[J]. Diabetologia,2019,62(4):644-654. [11] Kozlitina J,Smagris E,Stender S,et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet,2014,46(4):352-356. [12] Mancina R M,Dongiovanni P,Petta S,et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent[J]. Gastroenterology,2016,150(5):1219-1230.e1216. [13] Abul-Husn N S,Cheng X,Li A H,et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease[J]. N Engl J Med,2018,378(12):1096-1106. [14] Stickel F,Lutz P,Buch S,et al. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers[J]. Hepatology,2020,72(1):88-102. [15] Emdin C A,Haas M E,Khera A V,et al. A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease[J]. PLoS Genet,2020,16(4):e1008629. [16] Valenti L,Malvestiti F. From human genetics to therapy: targeting alcohol and steatotic liver disease via the FGF21 liver-brain axis[J]. J Hepatol,2026,84(6):1015-1017. [17] Rosoff D B,Wagner-deTurck J,Perlstein T,et al. Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease[J]. J Hepatol,2026,84(6):1031-1044. [18] Bianco C,Jamialahmadi O,Pelusi S,et al. Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores[J]. J Hepatol,2021,74(4):775-782. [19] Armisen J,Rauschecker M,Sarv J,et al. AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials[J]. J Hepatol,2025,83(1):31-42. [20] Sanyal A J,Taubel J,Badri P,et al. Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis[J]. J Hepatol,2025,83(4):838-848. [21] Harrison S A,Rolph T,Knott M,et al. FGF21 agonists: an emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond[J]. J Hepatol,2024,81(3):562-576. [22] Harrison S A,Bedossa P,Guy C D,et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med,2024,390(6):497-509. [23] Sanyal A J,Newsome P N,Kliers I,et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis[J]. N Engl J Med,2025,392(21):2089-2099. |